---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Pharmacodynamics"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Pharmacodynamics. Topics: Phase 1 interim: nadir prekallikrein by weight-based dose; Phase 1: 6 mg/kg single dose; Phase 1: 300 mg (plus or minus 25 mg) single fixed dose, prospectus; Phase 1: 300 mg single dose, congress reports; 10 further topics. 14 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### Phase 1 interim: nadir prekallikrein by weight-based dose

> “Mean nadir PKK levels were 39% (n=6), 14% (n=6), and 20% (n=5) of baseline following single doses of 0.4, 1.0, and 2.0 mg/kg, respectively.”
> “Cohort 2 PKK mean level remains 21% 99 days post-dose.”

Source: [Smith et al. (2023)](https://www.annallergy.org/article/S1081-1206%2823%2900702-0/fulltext)

<a id="topic-2.1.2.6.2-2"></a>

### Phase 1: 6 mg/kg single dose

> “we observed at the 6 mg/kg dose level that a single injection reduced circulating PKK/KK levels by a mean of 94% (88% to 97%, median 96%) at nadir and maintained 84% mean suppression (78% to 92%, median 82%) at 6 months.”
> “Three of the four participants at this dose level reached below LLOQ for PKK/KK levels at nadir.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.2.6.2-3"></a>

### Phase 1: 300 mg (plus or minus 25 mg) single fixed dose, prospectus

> “When analyzed by total fixed dose, we observed in healthy volunteers that following a single 300 mg +/- 25 mg achieved comparable performance, exceeding 90% mean reduction (84% to 96%, median 95%) at nadir with at least 80% mean suppression (65% to 90%, median 83%) sustained through the six-month timepoint (Day 169, as defined in our Phase 3 STOP-HAE trial)”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.2.6.2-4"></a>

### Phase 1: 300 mg single dose, congress reports

> “In Phase 1, a single SC injection of ADX-324 at 300 mg (±25 mg) achieved a mean PKK-KK reduction from baseline of over 90% at nadir, with >80% reduction maintained through Day 169.”
> “In HV, the 300 mg dose, not a lower one, achieved a 93% mean PKK-KK reduction at nadir and an 80% mean reduction at 6 month”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

> “A single SC injection of ADX-324 of 300 mg (± 25 mg) achieved a mean (SEM) PKK-KK reduction from baseline of > 90% at nadir, and > 80% reduction % maintained out to Day 169 (Week 25)”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

> “In Phase 1, a single SC dose of 300 mg reduced plasma kallikrein levels to over 90% at nadir, with maintenance of 80% reduction through Week 25.”

Source: [Cancian et al. (2026a)](https://www.adarx.com/wp-content/uploads/2026/06/EAACI-2026_Cancian-et-al-abstract-vF.pdf)

<a id="topic-2.1.2.6.2-5"></a>

### Phase 1: 300 mg single dose, sponsor press release

> “The 300 mg dose showed a 93% reduction at the lowest point, with 80% reduction maintained through Day 169.”

Source: [ADARx Pharmaceuticals onvuzosiran data announcement (2026)](https://www.adarx.com/adarx-pharmaceuticals-presents-onvuzosiran-data-supporting-potential-for-sustained-attack-free-rates-with-reduced-treatment-burden-in-patients-with-hae/)

<a id="topic-2.1.2.6.2-6"></a>

### Phase 1: 300 mg dose cohort as attributed in the November 2026 corporate presentation

> “Phase 1 support: 94% mean (88-97%) reduction at nadir, 84% mean (78-92%) reduction at 6mo at 300 mg +/-25 mg Q6M”

Source: [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)

<a id="topic-2.1.2.6.2-7"></a>

### Onset: lag to full prekallikrein inhibition

> “One known feature of siRNA therapeutic candidates such as onvuzosiran is lag time of about 22 days between initial treatment and full inhibition.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.2.6.2-8"></a>

### Phase 2a: prekallikrein reduction in participants with HAE compared with healthy volunteers

> “The PD results showed similar PKK inhibition between healthy volunteers in the Phase 1 clinical trial and HAE patients.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

> “In Phase 2, one patient received 122.5 mg and two patients received 245 mg.”
> “Their PKK-KK reductions mirrored those observed in healthy subjects dosed with ADX-324 at similar levels, supporting the Phase 3 target >80% PKK-KK reduction throughout 6 months in HAE patients at the 300 mg dose.”

Source: [Murai et al. (2026)](https://doi.org/10.1016/j.jaci.2025.12.095)

> “In Phase 2, HAE patients experienced plasma kallikrein levels reductions comparable to those seen in Phase 1.”

Source: [Cancian et al. (2026a)](https://www.adarx.com/wp-content/uploads/2026/06/EAACI-2026_Cancian-et-al-abstract-vF.pdf)

<a id="topic-2.1.2.6.2-9"></a>

### Phase 2a: prekallikrein suppression threshold associated with absence of attacks

> “We also correlated the episodes of attack with the PKK levels and found that no attacks occurred when the PKK suppression was >80%, suggesting that >80% suppression is potentially needed to achieve a maximal attack-free state.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

> “Notably, Phase 2 patients with >80% PKK-KK reductions experienced no HAE attacks, further supporting the potential of 300 mg Q6M to improve attack-free rates.”

Source: [Murai et al. (2026)](https://doi.org/10.1016/j.jaci.2025.12.095)

> “The patients’ data also supports that PKK-KK response can be used to predict HAE attacks and PKK-KK reductions > 70% are likely to prevent HAE attacks.”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

> “No attacks observed when PKK & KK reduction >80%”

Source: [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)

<a id="topic-2.1.2.6.2-10"></a>

### Preclinical studies: serum prekallikrein after a single 4 mg/kg dose in nonhuman primates

> “Following a single 4 mg/kg SC dose of onvuzosiran to NHPs (n=2), serum PKK/KK levels were assessed over a 92-day period by enzyme-linked immunosorbent assay (ELISA) and compared to the baseline level prior to dosing (Figure 12).”
> “Administration of onvuzosiran led to a >80% reduction of serum PKK from Day 22 through Day 78, with a 94% reduction of serum PKK at nadir on Day 50.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.1.2.6.2-11"></a>

### Preclinical studies: prekallikrein suppression at 200 mg/kg in nonhuman primates

> “NHP study shows deep suppression of prekallikrein with no safety concerns at supratherapeutic doses”

Source: [Cancian et al. (2026b)](https://www.adarx.com/wp-content/uploads/2026/06/Onvuzosiran-Provides-Deep-and-Sustained-Reduction-of-Plasma-Kallikrein-Levels-for-the-Treatment-of-HAE.pdf)

> “Results from the high dose NHP study showed no adverse events, supporting the safety of 300 mg dose, and reduction of prekallikrein protein levels as well as prekallikrein activity.”

Source: [Riedl et al. (2026b)](https://www.annallergy.org/article/S1081-1206%2826%2900563-6/fulltext)

<a id="topic-2.1.2.6.2-12"></a>

### Preclinical studies: projected dosing interval from nonhuman primate data

> “our pre-clinical studies in non-human primates have confirmed the likelihood for a bi-annual, and possibly annual, low volume subcutaneous dose regimen for ADX-324”

Source: [ADARx Pharmaceuticals (2023)](https://www.adarx.com/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324/)

<a id="topic-2.1.2.6.2-13"></a>

### Nonclinical toxicology: nonhuman primates and rabbits

> “In safety pharmacology, repeat-dose toxicology, and genotoxicity studies in NHPs, we observed no adverse effects with onvuzosiran, and NOAELs were established at the highest doses tested (up to 200 mg/kg subacute and 96 mg/kg chronic).”
> “Reproductive and developmental studies in rabbits showed no drug-related effects on fertility or embryo-fetal development.”
> “We observed a 25-fold safety margin at the 300 mg clinical dose.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

> “Results from the high dose NHP study showed no adverse events, supporting the safety of 300 mg dose (5 mg/kg).”

Source: [Cancian et al. (2026a)](https://www.adarx.com/wp-content/uploads/2026/06/EAACI-2026_Cancian-et-al-abstract-vF.pdf)

<a id="topic-2.1.2.6.2-14"></a>

### Nonclinical toxicology: off-target effects observed in rats

> “our determination that rat is not an appropriate species for the evaluation of the long-term safety of onvuzosiran may be incorrect, and the off-target effects and lack of pharmacologic activity that we observed in our preclinical rat studies may prove to be relevant to our ongoing and future onvuzosiran clinical trials.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
